This report was first published by Endpoints News. To see the original version, click here
SAN DIEGO — In early cuts of data, the next iteration of KRAS drugs for lung cancer appears to bear more promise than the first.
KRAS mutations drive around a quarter of all cancer cases and had been an elusive target until recently. The first two KRAS agents — Bristol Myers Squibb’s Krazati and Amgen’s Lumakras — were developed for one mutation called G12C that makes up roughly one in eight non-small cell lung cancer cases. They represented a scientific breakthrough but ultimately elicited marginal benefit in lung cancer.
您已阅读12%（617字），剩余88%（4477字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。